Study Title

A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney Cancer

Study Details

Description:

The aim of this study was to establish and optimize the [18F]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) was evaluated.

Sponsor:

RenJi Hospital

Contacts:

Weijun Wei, Ph.D. & M.D.

wwei@shsmu.edu.cn

15000083153

Wei Zhai, Ph.D. & M.D.

jacky_zw2002@hotmail.com

18701771959

Government Study Link:

NCT06680089 - Click here to see study on

ClinicalTrials.gov

Drug Details

[18F]RCCB6
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • CD70

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468